Medical device company ICU Medical (NASDAQ: ICUI) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 5.1% year on year to $560.4 million. Its non-GAAP profit of $2.44 per share was 13.6% above analysts’ consensus estimates.

For more on ICU Medical, read our free full research report.

Revenue growth

Examining a company’s long-term performance can provide clues about its quality. Even a bad business can perform well for one or two quarters, but a high-quality one grows for years. ICU Medical’s revenue grew at a decent 11.5% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

Long-term growth matters most, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ICU Medical’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 2.6% over the last two years.

This quarter, ICU Medical reported year-on-year revenue growth of 5.1%, and its $560.4 million in revenue exceeded Wall Street’s consensus estimates by 1.5%.

Looking ahead, sell-side analysts expect revenue to grow 3.7% over the next 12 months, according to S&P. While this projection implies its newer products and services will fuel better top-line performance, it is still below average for the sector.

Adjusted operating margin

Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes and interest on debt – metrics less connected to business fundamentals.

ICU Medical has done a decent job managing its cost base over the last five years. The company has produced an average adjusted operating margin of 13.4%, higher than the broader healthcare sector.

Analyzing the trend in its profitability, ICU Medical’s adjusted operating margin rose by 2.5 percentage points over the last five years, as its revenue growth gave it operating leverage. The company’s two-year trajectory shows its performance was mostly driven by its recent improvements.

In Q3, ICU Medical generated an adjusted operating margin of 11.5%, down 5.3 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings per share

Long-term changes in earnings per share (EPS) matter for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

ICU Medical’s EPS grew at an unimpressive 3.4% compounded annual growth rate over the last five years, lower than its 11.5% annualized revenue growth. However, its adjusted operating margin improved during this time, indicating that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings.

A closer look at ICU Medical’s earnings helps explain the drivers of its performance. A five-year view shows ICU Medical has diluted its shareholders, growing its share count by 15.7%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q3, ICU Medical reported adjusted EPS of $2.44, up from $2.03 in the same quarter last year. This result easily cleared analysts’ consensus estimates. Over the next 12 months, Wall Street expects ICU Medical’s full-year EPS to grow 6% from $8.69 to $9.21, according to S&P.

Key takeaways from ICU Medical’s Q3 results

ICU Medical delivered on both revenue and earnings this quarter, topping Wall Street’s consensus estimates for revenue and EPS. Those beats were key positives in the results. Shares remained flat at $167.46 immediately after the release.

To assess whether to invest in ICU Medical, consider valuation, business quality and the latest earnings. Read our full research report here (it’s free).